4-aminobutyrate aminotransferaseGenealiases: GABA-AT · GABAT · NPD009
Q-omics provides the consensus-scored ABAT profile across patient tissues and cancer cell-line models. ABAT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ABAT is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ABAT protein abundance shows 21,785 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where ABAT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABAT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABAT survival associations across molecular data types. ABAT RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABAT RNA expression–survival associations across cancer types. High ABAT expression shows favorable associations in KIRP, ACC, KIRC, LUAD, BRCA and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ABAT RNA expression.
This table summarizes ABAT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ABAT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABAT shows lower tumor expression in KIRC, KICH, KIRP, LIHC, THCA and READ. The KIRC box plot shows higher ABAT RNA expression in normal versus tumor tissue (log2 FC = −2.150, t-test p < 0.001).
This table shows molecular features associated with ABAT in patient tissues and cancer cell lines. In patient samples, ABAT shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ABAT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
